Leerink Partners Upgrades Twist Bioscience to Outperform, Announces $70 Price Target

Benzinga Newsdesk www.benzinga.com Positive 90.2%

Neg 0% Neu 0% Pos 90.2%

Leerink Partners analyst Puneet Souda upgrades Twist Bioscience (NASDAQ:TWST) from Market Perform to Outperform and announces $70 price target.